| Identification | Back Directory | [Name]
Narsoplimab | [CAS]
2108782-45-0 | [Synonyms]
Narsoplimab
Narsoplimab (anti-MASP2)
Research Grade Narsoplimab(DHA04501) |
| Hazard Information | Back Directory | [Uses]
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2[1]. | [in vivo]
Narsoplimab (10 mg/kg; i.v.; WT and Masp2-/- (KO) mice) decreases percentage of lymphocytes (Lym%) and increases percentage of neutrophils (Neu%)[1]. | Animal Model: | WT and Masp2-/- (KO) mice (C57BL/6N, female, 12-15 weeks old)[1] | | Dosage: | 10 mg/kg | | Administration: | Intravenous injection | | Result: | Decreased percentage of lymphocytes (Lym%) and an increased percentage of neutrophils (Neu%). |
| [References]
[1] Gao T, et, al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Signal Transduct Target Ther. 2022 Sep 14;7(1):318. DOI:10.1038/s41392-022-01133-5 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|